OncLive TV

Robert L. Coleman, MD, FACOG, FACS, discusses the utility of biomarkers in precision medicine.

William R. Gwin III, MD, discusses potential areas of investigation with the combination of alpha-tocopheryloxyacetic acid (alpha-TEA) and trastuzumab (Herceptin) in breast cancer.

Parameswaran Hari, MD, MRCP, discusses the current and potential future utility of ixazomib (Ninlaro) maintenance in multiple myeloma.

Shaji K. Kumar, MD, discusses key takeaways from the phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.

Hun Ju Lee, MD, discusses novel targets in lymphomas and leukemias.

Jesus G. Berdeja, MD, discusses updated safety results from the ongoing phase 1b/2 CARTITUDE-1 trial (NCT03548207) with the CAR T-cell therapy JNJ-4528 in multiple myeloma.

Michael J. Morris, MD, discusses the promising future of prostate-specific membrane antigen–targeted PET imaging in prostate cancer.

Preetesh Jain, MD, PhD, discusses the activity of venetoclax (Venclexta) in mantle cell lymphoma (MCL).

Mark M. Awad, MD, PhD, discusses acquired resistance to MET inhibitors in MET exon 14 skipping (METex14)–mutated non–small cell lung cancer (NSCLC).

Jia Ruan, MD, PhD, discusses the impact of BTK inhibitors in mantle cell lymphoma (MCL).

Jeff P. Sharman, MD, discusses unmet clinical needs in the treatment of patients with high-risk relapsed/refractory chronic lymphocytic leukemia.

Denise Yardley, MD, discusses treatment considerations for patients with advanced breast cancer who have visceral metastases.

Brian M. Slomovitz, MD, discusses the importance of developing sequencing strategies in endometrial cancer treatment.

David Polsky, MD, PhD, on the association between circulating tumor DNA and survival in melanoma.

Jonathan Mizrahi, MD, discusses the addition of veliparib to chemotherapy in BRCA1/2 or PALB2-mutated pancreatic cancer.

Ignace B. Vergote, MD, PhD, discusses the need to develop novel therapies in endometrial cancer.

Thomas Hope, MD, discusses the rationale for using 68Ga-PSMA-11 PET to detect pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Gareth J. Morgan, MD, PhD, discusses the evolution of treatment options in multiple myeloma.

Ursula A. Matulonis, MD, discusses final data from the phase 2 KEYNOTE-100 trial with pembrolizumab (Keytruda) in advanced recurrent ovarian cancer.

Ritu Salani, MD, discusses opportunities for precision medicine in cervical cancer.

James Weitzman, MD, medical oncologist, Emerson Hospital and Waltham Cancer Center of Massachusetts General Cancer Center, discusses sequencing challenges in multiple myeloma treatment.

Courtney DiNardo, MD, MSCE, iscusses findings from a pooled analysis examining venetoclax (Venclexta) combination treatment in acute myeloid leukemia.

Caron Jacobson, MD, discusses the benefit of axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed/refractory follicular lymphoma.

Fred Saad, MD, FRCS, discusses the randomized phase 3 SPARTAN trial in nonmetastatic castration-resistant prostate cancer.

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.

Hun Ju Lee, MD, discusses early efficacy data from a phase 1b/2 study of the investigational ROR1 inhibitor cirmtuzumab in combination with ibrutinib in patients with relapsed/refractory mantle cell lymphoma.

Jamie E. Chaft, MD, discusses considerations for restarting immunotherapy in patients with lung cancer.

Michael Wang, MD, discusses the safety and effectiveness of the autologous anti-CD19 CAR T-cell therapy KTE-X19 in patients with higher- versus lower-risk mantle cell lymphoma.

William K. Kelly, DO, discusses results from a phase 1b dose-finding study evaluating the combination of radium-223 dichloride (Xofigo) plus niraparib (Zejula) in patients with metastatic castration-resistant prostate cancer.